Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226864 (US9328096, 557) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.02 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM227148 (US9328096, 836) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.04 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226929 (US9328096, 617) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.17 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226759 (US9328096, 452) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.43 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226847 (US9328096, 540) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.51 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226527 (US9328096, 220) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.71 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226611 (US9328096, 304) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.71 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226486 (US9328096, 179) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.74 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226998 (US9328096, 686) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.77 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226353 (US9328096, 46) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.81 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226346 (US9328096, 39) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.94 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM227052 (US9328096, 740) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.02 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226514 (US9328096, 207) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.06 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226999 (US9328096, 687) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.27 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226472 (US9328096, 165) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.45 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226881 (US9328096, 574) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.46 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226481 (US9328096, 174) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.53 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226483 (US9328096, 176) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226992 (US9328096, 680) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.65 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226487 (US9328096, 180) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.80 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226807 (US9328096, 500) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.84 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226729 (US9328096, 422) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.96 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226458 (US9328096, 151) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.98 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226485 (US9328096, 178) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.05 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226347 (US9328096, 40) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.17 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226882 (US9328096, 575) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.21 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226874 (US9328096, 567) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.22 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM227058 (US9328096, 746) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.25 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226529 (US9328096, 222) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.37 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226445 (US9328096, 138) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.41 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226838 (US9328096, 531) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.41 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226521 (US9328096, 214) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.63 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226352 (US9328096, 45) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.92 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226865 (US9328096, 558) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.02 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226477 (US9328096, 170) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.03 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226853 (US9328096, 546) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.14 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226476 (US9328096, 169) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.22 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226879 (US9328096, 572) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.36 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226862 (US9328096, 555) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.41 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226845 (US9328096, 538) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.46 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM227054 (US9328096, 742) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.5 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM227000 (US9328096, 688) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.56 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226441 (US9328096, 134) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.61 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226856 (US9328096, 549) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.66 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226494 (US9328096, 187) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.67 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226866 (US9328096, 559) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.68 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226850 (US9328096, 543) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.69 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226465 (US9328096, 158) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.71 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226460 (US9328096, 153) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.72 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity nerve growth factor receptor [441-796] (Homo sapiens (Human)) | BDBM226877 (US9328096, 570) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.73 | n/a | n/a | n/a | n/a | n/a | 37 |
Pfizer Inc. US Patent | Assay Description TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR... | US Patent US9328096 (2016) BindingDB Entry DOI: 10.7270/Q2FN152J | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 800 total ) | Next | Last >> |